• Curis Inc., of Lexington, Mass., said partner Roche AG, of Basel, Switzerland, began a Phase Ib/II study with Erivedge (vismodegib) in patients with relapsed/ refractory acute myelogenous leukemia and relapsed/refractory high-risk myelodysplastic syndrome.